CPMD CANNAPHARMARX, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1081938 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.8%
TTM net income YoY-100.1%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-88.8%
Operating margin-170.1%
Net margin-666.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-123.3%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets547.3%
Debt / equity—
Current ratio0.04x
Interest coverage-1.91x
Cash quality & payout
Operating cash flow / net income0.01x
Accruals ratio-122.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.36M | $820,137 | $0 | $0 | $0 |
| Cost of revenue | $3.45M | $3.76M | $0 | — | — |
| Gross profit | -$2.08M | -$2.93M | $0 | — | — |
| SG&A expense | $489,641 | $145,713 | $703,596 | $2.23M | $852,645 |
| Operating income | -$3.35M | -$3.63M | -$1.58M | -$5.21M | -$2.99M |
| Interest expense | $1.96M | $2.26M | $1.69M | $2.29M | $1.51M |
| Pretax income | — | — | — | -$8.53M | -$8.83M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$11.13M | -$9.91M | $3.69M | -$8.53M | -$8.83M |
| EBITDA | — | -$3.63M | -$1.45M | -$4.92M | -$2.99M |
| EPS (basic) | — | — | — | 0.04 | 0.12 |
| EPS (diluted) | -0.02 | -0.02 | 0.01 | 0.04 | 0.12 |
| Weighted avg. shares (diluted) | 662.50M | 625.28M | 308.94M | 211.04M | 74.69M |
| Balance sheet | |||||
| Cash & equivalents | $1,804 | $2,156 | $650 | $2,317 | $27,767 |
| Receivables | $164,430 | $1,747 | $0 | — | — |
| Inventory | $1.12M | $996,250 | $1.13M | — | — |
| Current assets | $1.31M | $1.02M | $1.20M | $100,014 | $29,538 |
| PP&E, net | $127,029 | $137,237 | $161,540 | $107,780 | $6,032 |
| Total assets | $7.02M | $10.84M | $11.75M | $5.41M | $114,330 |
| Current liabilities | $31.59M | $25.75M | $18.73M | $17.43M | $13.04M |
| Total liabilities | $37.17M | $30.65M | $23.90M | $22.76M | $13.04M |
| Shareholders' equity | -$30.15M | -$19.81M | -$12.15M | $17.34M | -$12.93M |
| Shares outstanding | 662.50M | 662.50M | 440.75M | 274.12M | 125.51M |
| Cash flow statement | |||||
| Operating cash flow | -$789,102 | -$1.70M | -$2.27M | -$1.45M | -$2.41M |
| Capital expenditure | $5,519 | $0 | $80,634 | — | — |
| Free cash flow | -$794,621 | -$1.70M | -$2.36M | — | — |
| Investing cash flow | $794,269 | $1.70M | -$80,634 | -$115,998 | $493,623 |
| Financing cash flow | -$5,519 | $0 | $2.35M | $1.40M | $1.34M |
| Depreciation & amortization | — | $0 | $127,847 | $294,934 | $2,708 |
| Stock-based compensation | — | — | — | $180,979 | $363,050 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.